Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis |
| |
| Authors: | Christos C Zouboulis Holger Seltmann Theodosios Alestas |
| |
| Institution: | 1. Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany;2. Laboratory for Biogerontology, Dermato‐Pharmacology and Dermato‐Endocrinology, Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Berlin, Germany;3. The authors contributed equally to the study.;4. Christos C. Zouboulis is owner of a relevant international patent entitled ‘Treatment of acne with lipoxygenase inhibitors’ (priority number DE20011021252 of 30.04.2001). |
| |
| Abstract: | Please cite this paper as: Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Experimental Dermatology 2010; 19: 148–150. Abstract: Arachidonic acid (AA) activates the 5‐lipoxygenase, induces leukotriene‐B4 (LTB4) synthesis, enhances interleukin‐6 (IL‐6) release and increases intracellular neutral lipids in human sebocytes. Moreover, the enzymes of LTB4 biosynthesis are activated in acne‐involved sebaceous glands. Zileuton a 5‐lipoxygenase inhibitor, reduces the number of inflammatory acne lesions and lipogenesis in patients with acne. In this study, we investigated the activity of zileuton on LTB4 generation, lipid content and IL‐6 and ‐8 release from human SZ95 sebocytes in vitro. Pretreatment with zileuton partially prevented the AA‐induced LTB4 and IL‐6 release and increased neutral lipid content. IL‐6 release and neutral lipid content were also reduced under long‐term zileuton treatment. In conclusion, zileuton prevents the activation of the leukotriene pathway and enhancement of lipogenesis by AA in human sebocytes in vitro. |
| |
| Keywords: | leukotrienes lipids sebaceous gland treatment Zileuton |
|
|
